Takeda (TAK)
16.82
-0.05 (0.30%)
Upcoming Events
Latest Headlines
Takeda psoriasis drug shows skin clearance in Phase 3 trials
July 16, 2026 6:00 PM - StreetInsider
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
July 16, 2026 6:00 PM - BizWire
Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello
July 13, 2026 6:27 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski
July 13, 2026 6:26 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard
July 13, 2026 6:26 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Furney Natalie Anne Marie
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Greenway Nicola Deidre Petal
July 13, 2026 6:25 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Shannon Elaine Mary
July 13, 2026 6:24 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Ibrahim Ramy Riad Ahmed
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Farajallah Awny Samaan Botros
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Pacheco Rhonda Janice
July 13, 2026 6:23 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Plump Andrew Stewart
July 13, 2026 6:22 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Bitetti Teresa Marie
July 13, 2026 6:22 AM - SEC Filing
Form 144 TAKEDA PHARMACEUTICAL Filed by: Kim Julie So-Young
July 13, 2026 6:08 AM - SEC Filing
Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products
July 12, 2026 7:00 PM - BizWire
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 09
July 9, 2026 6:03 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jul 08
July 8, 2026 6:03 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: GILLIS STEVEN
July 6, 2026 6:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: MARAGANORE JOHN
July 6, 2026 6:29 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Reed Kimberly A.
July 6, 2026 6:28 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Iijima Masami
July 6, 2026 6:14 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: BROUSSARD BRUCE D
July 6, 2026 6:12 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Stoffels Paulus
July 6, 2026 6:11 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kimura Koichiro
July 6, 2026 6:11 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Tsusaka Miki
July 6, 2026 6:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Miyabashira Asuka
July 6, 2026 6:10 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furuta Milano
July 6, 2026 6:09 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Platford Giles Richard
July 6, 2026 6:08 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Smoter Jennifer Marie
July 6, 2026 6:08 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ibrahim Ramy Riad Ahmed
July 6, 2026 6:07 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Greenway Nicola Deidre Petal
July 6, 2026 6:06 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Farajallah Awny Samaan Botros
July 6, 2026 6:06 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Furney Natalie Anne Marie
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pacheco Rhonda Janice
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Pignagnoli Agosti Marcello
July 6, 2026 6:05 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Ricci Gabriele
July 6, 2026 6:04 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Shannon Elaine Mary
July 6, 2026 6:04 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Duprey Lauren Rusckowski
July 6, 2026 6:03 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Bitetti Teresa Marie
July 6, 2026 6:03 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Kim Julie So-Young
July 6, 2026 6:02 PM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Jul 01 Filed by: Plump Andrew Stewart
July 6, 2026 6:01 PM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Kimura Koichiro
July 6, 2026 11:32 AM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: BROUSSARD BRUCE D
July 6, 2026 11:32 AM - SEC Filing
Form 3 TAKEDA PHARMACEUTICAL For: Jun 24 Filed by: Stoffels Paulus
July 6, 2026 11:32 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY6,700 at Macquarie
June 30, 2026 6:17 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 29
June 29, 2026 6:04 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 26
June 26, 2026 6:33 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:15 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:07 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 24
June 24, 2026 6:05 AM - SEC Filing
Takeda names Julie Kim as president and CEO after shareholder vote
June 24, 2026 3:14 AM - StreetInsider
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
June 24, 2026 3:05 AM - BizWire
Form IRANNOTICE TAKEDA PHARMACEUTICAL
June 17, 2026 6:32 AM - SEC Filing
Form 20-F TAKEDA PHARMACEUTICAL For: Mar 31
June 17, 2026 6:07 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,500 at Nomura/Instinet
June 16, 2026 7:12 AM - StreetInsider
Goldman Sachs Reiterates Neutral Rating on Takeda Pharmaceutical (4502:JP) (TAK)
June 16, 2026 12:22 AM - StreetInsider
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1
June 15, 2026 12:00 PM - BizWire
Takeda's zasocitinib beats deucravacitinib in psoriasis study
June 11, 2026 7:00 AM - StreetInsider
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
June 11, 2026 7:00 AM - BizWire
FDA accepts Takeda's application for pediatric ENTYVIO treatment
June 9, 2026 4:30 PM - StreetInsider
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
June 9, 2026 4:30 PM - BizWire
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 09
June 9, 2026 6:10 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
June 5, 2026 6:30 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 05
June 5, 2026 6:28 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: Jun 01
June 1, 2026 6:07 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Raised to JPY7,900 at Citi
May 26, 2026 6:19 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: May 26
May 26, 2026 6:14 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 26
May 26, 2026 6:12 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 26
May 26, 2026 6:11 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 26
May 26, 2026 6:11 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 26
May 26, 2026 6:10 AM - SEC Filing
Form SD TAKEDA PHARMACEUTICAL
May 22, 2026 11:27 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 19
May 19, 2026 6:11 AM - SEC Filing
Takeda Pharmaceutical (4502:JP) (TAK) PT Lowered to JPY6,400 at Macquarie
May 14, 2026 6:28 AM - StreetInsider
Form 6-K TAKEDA PHARMACEUTICAL For: May 13
May 13, 2026 6:12 AM - SEC Filing
Form 6-K TAKEDA PHARMACEUTICAL For: May 13
May 13, 2026 6:07 AM - SEC Filing
Takeda reports revenue decline but maintains profit margins in fiscal 2025
May 13, 2026 5:46 AM - StreetInsider
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
May 13, 2026 2:38 AM - BizWire
Form 3 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Smoter Jennifer Marie
May 5, 2026 6:32 AM - SEC Filing
Takeda reports positive Phase 2/3 trial results for TAK-881 in immune disorder
May 4, 2026 8:00 AM - StreetInsider
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
May 4, 2026 8:00 AM - BizWire
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Weber Christophe Pierre
April 28, 2026 6:12 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Plump Andrew Stewart
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Duprey Lauren Rusckowski
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Pignagnoli Agosti Marcello
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Ricci Gabriele
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Bitetti Teresa Marie
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Furuta Milano
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Kim Julie So-Young
April 28, 2026 6:11 AM - SEC Filing
Form 4 TAKEDA PHARMACEUTICAL For: Apr 27 Filed by: Platford Giles Richard
April 28, 2026 6:11 AM - SEC Filing
Full Article List
